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Erythrocytosis is a condition in which the haemoglobin 
concentration or red cell mass is increased to abnormally high 
levels. This may be primary, due to haematologic malignancies, 
or secondary to phenomena which are either physiologically 
appropriate, such as long-standing hypoxia, or physiologically 
inappropriate, resulting from conditions with increased 
erythropoietic drive. Erythrocytosis results in hyperviscosity, 
which may cause dysfunction or infarction in cerebrovascular, 
coronary arterial or peripheral vascular circulations. 
Therapeutic venesection plays an important role in the 
management of patients with an expanded red cell mass. The 
beneficial effect of reduction in viscosity on microvascular 
perfusion is, however, offset to a degree by the concurrent 
decrease in oxygen carrying capacity per unit volume occurring 
after phlebotomy. Thus, overall tissue oxygenation will improve 
with more efficient perfusion, provided that the perfusing nlood 
contains sufficient oxygen to meet metabolic requirements. 
Accordingly, the physician is confronted with the question of 
which packed cell volume (PCV) will best serve the patient's 
needs in terms of this specific end-point. There is some 
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evidence to suggest that the PCV should be less than 0.50 L·L-1 
in erythrocytosis secondary to hypoxic lung disease1 , and that 
improvement in pulmonary haemodynamics, oxygen transport and 
cerebral blood flow will follow venesection to this level 1- 4 • 
Despite a consensus derived from several publications that return 
of PCV into the normal range protects patients from morbidity and 
mortality, debate continues about the extent of venesection 
necessary for optimal tissue oxygen delivery. 
The aim of this study was to determine the level of packed 
cell volume for optimal function in a group of patients with 
erythrocytosis by performing a variety of investigations at 
presentation and during progressive venesection to PCV of 
0. 4 0 L · L- 1 • 
This introductory literature review addresses the background 
to the study by looking at the physiology of erythropoiesis; the 
classification and diagnosis of erythrocytosis; the morbidity 
associated with erythrocytosis; and the management of 
erythrocytosis. 
1.1 Control of red cell production 
Efficient functioning of the body deper}s upon an adequate 
supply of oxygen to the tissues. This in turn depends upon the 
ability of blood to carry oxygen and the flow of blood through 
the tissues. Haemoglobin is essential for the carriage of oxygen 
due to its unique reversible binding characteristics5 • The 
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amount of haemoglobin is under careful physiological control to 
maintain an optimal concentration for oxygen carriage. There are 
two conflicting forces which require to be balanced. These are 
haemoglobin concentration and erythrocyte mass which are opposed 
by the rheological disturbances resulting from increased 
viscosity caused by increases in haemoglobin concentration or 
erythrocyte mass. In most individuals the red cell mass is 
efficiently modulated so that effective function can continue. 
The initial response by the body to changes in oxygen 
delivery involves cardiovascular and respiratory adjustments, 
these include increases in cardiac output and minute 
ventilation6 • Conformational changes in the haemoglobin molecule 
resulting in local changes in haemoglobin affinity to increase or 
decrease the amount of oxygen bound to haemoglobin occur 
continuously5 • If the disturbance lasts beyond a few minutes, 
increased glycolytic activity results in increases in the levels 
of the intermediate metabolite, 2,3-diphosphoglycerate. 
Increased levels of this compound cause decreased affinity of 
haemoglobin for oxygen and facilitates release of oxygen in the 
tissues7 ,s. 
More prolonged homeostasis of oxygen delivery (after 1 to 2 
hours) is by feedback control oi red cell production. Oxygen 
deprivation of tissues results in release or activation of 
erythropoietin by the kidneys. 
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Erythropoietin is a glycoprotein produced predominantly by 
the kidneys 9 • A heme-containing protein senses oxygen lack and 
causes synthesis and release of erythropoietin
10 • Erythropoietin 
stimulates the differentiation and maturation of progenitor cells 
conunitted to the erythroid lineage (BFU-E)
11 • These then mature 
and proliferate to produce mature erythroid forms. It appears 
that there is an erythropoietin-dependent negative feedback 
system to regulate red cell production. The normal control of 
erythropoiesis is sununarised in figure 1.1
12 • 
Bone Marrow 
Stem cell -> BFU-E -> CFU-E -> Erythroid precursors 
Erythropoietin 
\ 




!Hb], Hb affinity 
/I~ _E_r_y_t_hropoietin synthesis..- 02 sensor 
Kidney 
Renal blood flow 
Renal 02 cons 
Figure 1.1: Control of erythropoiesis 
The most important consequence of increased PCV is increased 
whole-blood viscosity and the resulting complications. The 
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management of erythrocytosis depends upon the aetiology, the 
clinical manifestations, and complications. 
Erythrocytosis may be absolute or relative
13 • The 
distinction between relative and absolute erythrocytosis can only 
be definitively made on measurement of red cell mass and plasma 
volume by radio-isotopic techniques
14 •15 • Relative erythrocytosis 
is characterised by normal red cell mass and contracted plasma 
volume. Common causes of this syndrome (also termed "spurious 
erythrocytosis", "stress erythrocytosis" or "Gaisbock's 
syndrome") include smoking, heavy use of alcohol and diuretic 
use14 • Since the aetiology and management of this condition 
differ to other forms of erythrocytosis, this topic will not be 
considered further. 
1.2 Classification and diagnosis of erythrocytosis 
Absolute or true erythrocytosis is characterised by an 
expanded red cell mass. The origin of this expansion may be 
primary, because of malignant proliferation of haematopoietic 
cell lines, or secondary, because of uncontrolled production of 
erythropoietin or erythropoietin-like substance
13 • 
1.2.1 t'rimary erythrocytosis 
Primary erythrocytosis is usually due to polycythaemia vera 
(PV). PV is a rare haematologic malignancy characterised by 
excessive proliferation of erythroid, rnyeloid and megakaryocytic 
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elements of the bone marrow16 • The most usual presentation is 
with proliferation of myeloid constituents, with erythrocytosis 
or thrombocytosis. This eventually, in most cases, terminates in 
myelof ibrosis, myelodysplasia or blastic transformation
17-zo. The 
diagnosis of PV is made according to criteria laid down by the 
Polycythemia Vera Study Group. These criteria are to be found in 
table 1.1 13 • 
Table 1.1: Criteria for diagnosis of polycythaemia vera 
Categories 
Al Red cell mass 
Male: ~ 36 mL/kg 





Diagnosis acceptable with: Al+ A2 + A3 
Thrombocytosis 
Platelets> 400 X 109 /L 
wee > 12 X 109 /L 
(No fever/ infection) 
LAP > 100 
(No fever/ infection) 
Serum B12 > 900 pg/mL 
or: Al+ A2 + (any two from category B) 
1.2.2 Secordary erythrocytosis 
Secondary erythrocytosis is an absolute increase in red cell 
mass with normal or elevated plasma volume. This is usually due 
to continued erythropoietin stimulation of red cell production21 • 
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Occasional reports of erythrocytosis secondary to other factors, 
such as azidothymidine22 , are found, but these are uncommon. 
The causes of secondary erythrocytosis can be divided into 
those with increased erythropoietin drive secondary to diminished 
tissue oxygen supply ("physiologically appropriate"), and those 
in which autonomous over-production of erythropoietin occur 
("physiologically inappropriate"). Table 1.2 lists most of the 
described causes of secondary erythrocytosis. 
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Table 1.2: Causes of secondary erythrocytosis 
(Modified from Berlin13 ) 
1. "Physiologically appropriate" (decreased tissue oxygen 
supply) 
a. High altitude 
b. Hypoxic lung disease 
c. Congenital heart disease 
d. Sleep apnoea syndromes 
e. Obesity-hypoventilation syndrome 
f. Haemoglobinopathy 
g. Smoking 
h. Chronic liver disease23 •24 
2. "Physiogically inappropriate" 
a. Tumours 
i. Renal carcinoma25 
ii. Cerebellar haemangioblastoma26 
iii. Hepatoma 
iv. Uterine fibroids 




iii. Bartter's syndrome 
iv. Transplantation~ 
c. Miscellaneous 
i. Zidovudine therapy in AIDS 
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Secondary erythrocytosis due to diminished tissue oxygen 
supply is the most common cause of true erythrocytosis. 
Decreased tissue oxygen supply may occur as a result of high 
altitude ( decreased ambient oxygen tension) 
29 •
30 ; lung disease 
(ventilation-perfusion mismatching, diffusion gradient or 
hypoventilation) 31 • 32 ; or congenital heart disease and chronic 








• These conditions 
result in a chronic reduction in arterial oxygen saturation 
(Sa02 ) and sustained erythropoietin release. Occ
ult causes of 
erythrocytosis include the obesity-hypoventilation and sleep 
apnoea syndromes, which may present with normal daytime Sa02 , but 
marked falls in Sa02 during sleep
36 , 37 • 
Smoking causes an elevation in carboxyhaemoglobin (COHb), 
effectively reducing the amount of haemoglobin available for 
oxygen transport. COHb also causes a conformational change in 
haemoglobin structure, resulting in higher affinity of the 
haemoglobin molecule for oxygen~.~. 
This mechanism of left-shifting of the haemoglobin-oxygen 
dissociation curve is responsible for the tissue hypoxia and 
erythrocytosis seen in the haemoglobinopathies, many of which 
result in haemoglobin molecules with high affinity for oxygen and 
consequent tissue hypoxia40 • 
There is no doubt that the erythrocytosis seen in hypoxic 
lung disease and cyanotic congenital heart disease is often a 
physiological overshoot. The correlation between arterial oxygen 
saturation levels and red cell mass or 2,3-diphosphoglycerate 
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levels is poor41 . Some patients with secondary erythrocytosis 
can maintain a stable state with few symptoms and apparent side 
effects from erythrocytosis ("compensated"). A large number, 
however, are "decompensated" and PCV tends to rise with failure 
of negative feedback on erythropoiesis. These patients develop 
significant symptoms and problems from the elevated PCV and 
represent adaptive failure34 ,35 • 
Other causes of secondary erythrocytosis are uncommon and 
many mechanisms have been described, including tumour production 
of erythropoietin, reduced erythropoietin catabolism, regional 
renal or hepatic ischaemia and the production of erythropoietin-
like substances12,21,22,26,42-44. 
The cause of erythrocytosis can be established by following 
the algorithm portrayed in figure 1.2
13 • 16 , which describes the 
diagnostic steps to be taken during investigation. The diagnosis 
of erythrocytosis secondary to smoking is often made once all 
other causes have been excluded because measurement of COHb 





_ M > 36 ml/kg 
Normal •<1-------'-----...-, F > 32 ml/kg 
! l 
I 
Relative eryth~~~J [ ____ ...:___ ___ ~-----, 
- Arterial oxygen satur~ 
>• 92% • I 1 < 92% 
1 
l l .---..-, I Secondary erythrocytosis I 
CT head 
~ :
r IVP, U/S kidneys Ab I 
T 
norma 
Hg ~ No'fal Noral -+I Pr]-+ Abnrmal 
l 
Screen for sleep- Haemoglobinopathy 
related breathing Normal 
~---'·'----------, I Smokers' erythrocytosis I Ld_is_o_r_d_e_r ----~ j Primary erythrocytosis I 
Figure 1.2: Algorithm for evaluation of elevated PCV 
1.3 Complications of erythrocytosis 
Erythrocytosis is associated with a number of complications, 
most due to decreased blood flow or stasis as a result of 
increased whole-blood viscosity. Increases in pulmonary and 
systemic vascular resistance, left and right heart failure, 
vascular occ ,usive events (arterial occlusion, deep venous 
thrombosis, and cerebral vascular accidents), and decreased 
cerebral blood flow resulting in poor concentration, headaches 
and impaired performance are commonly found. 
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1.3.1 Changes in haemodynamic variables 
The effects of erythrocytosis on haemodynamic variables have 
been studied in a number of patients with erythrocytosis 
secondary to hypoxic lung disease and cyanotic congenital heart 
disease. In these patients it is difficult to divorce the 
effects of hypoxic pulmonary vasoconstriction and the inherent 
lung disease from the effects due to increased PCV and viscosity. 
Several of these studies2- 4 , 45 - 47 , smrunarised in table 1. 3, have 
repeated measurements of haemodynamic variables after therapeutic 
venesection. Changes in haemodynamics demonstrated under these 
conditions are thus likely to be due to the reduction in PCV and 
not the primary disease process alone. 
Studies involving patients with hypoxic lung disease have 
shown that reduction in PCV by venesection reduces pulmonary 
artery pressures at rest and during exercise, as well as reducing 
pulmonary and systemic vascular resistance. In particular, 
Weisse et al2 showed that reducing PCV from 0.62 to 0.50 L·L-
1 
reduced resting mean pulmonary artery pressure from 46 to 
38 mm Hg. The pulmonary vascular resistance fell from 803 to 
690 dyne·sec·cm-5 • Cardiac index was unaffected. There was no 
further fall in pulmonary artery pressure or pulmonary vascular 
resistance when the PCV was lowered to 0.44 L·L-
1 • The 
conclusion from this was that venesection to levels of lower than 
0.50 L·L-1 was not beneficial in terms of haemodynamic 
improvement. 
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Segel and Bishop3 showed that reducing PCV from 0.60 to 
0.44 L·L-1 in 15 patients with hypoxic lung disease resulted in 
small falls in pulmonary artery pressure and pulmonary vascular 
resistance, while cardiac index did not change. Similar trends 
with reduced pulmonary vascular resistance and pulmonary artery 
pressures after venesection are evident in the other studies. 
Although there is a degree of variability in the results, there 
is an overall trend for pulmonary and systemic vascular 
resistance at rest and on exercise to fall following venesection. 
This suggests that at least part of the increased vascular 
resistance is due to erythrocytosis. 
Chetty et al48 studied 15 patients with hypoxia due to 
chronic obstructive pulmonary disease before and after 
venesection from mean PCV 0.60 L·L-1 to 0.51 L·L-
1 • Exercise 
duration increased by 50% and maximum oxygen uptake by 25% with 
no significant changes in maximum exercise heart rate or minute 
ventilation. They did not measure haemodynamic variables 
directly but interpreted the improved exercise performance to 
mean increased cardiac output during maximum exercise. 
Similar, but small, improvements in haemodynamics at rest 
and on exercise accompanied reduction in PCV by venesection in 
PV47 • Oldershaw and Sutton33 studied 6 childre~ with cyanotic 
congenital heart disease and were able to show a 50% increase in 
maximum exercise capacity and a 30% increase in resting cardiac 
index after venesection from an initial PCV of 0.66 ± 0.01 to 
0.58 ± 0.01 L·L-1 • Heart rate, minute ventilation and arterial 
- 17 -




Author Patients Number PCV PA CI Rs Rp CI(ex) PA(ex) Rs(ex) Rp(ex) ~ 
L/L mmHg L/min/m2 dynes.s/cm
5 r-' (11 
r-' 
Weisse Hypoxic 12 0.62 46 2.8 1739 803 
. 
w 
et al lung dis 0.50 38 2.8 1677 690 
.. 
1975 0.44 38 3.0 1534 684 ::r:: I}) ,, 
Rakita Hypoxic 15 0.56 32 2.3 1872 730 
3 
0 
et al lung dis 0.54 30 2.3 1850 688 % 
1965 ~ 
f-· 
Segel & Hypoxic 15 0.60 47 3.3 1698 514 4.9 77 1440 636 
() 








Harrison Hypoxic 10 0.63 25 7.22 51. 6 
<LJ 
3 







Wallis Hypoxic 12 0.61 41 3.1 
:i 









Segel & P. vera 15 0.63 26 4.2 1504 124 5.9 40 1291 136 
'< 
rt 






PA: mean pulmonary artery pressure; CI: cardiac index; Rs: systemic vascular resistance; Rp: pulmonary vascular 
resistance; (ex): during exercise 
1.3.2 Vascular occlusive episodes 
Vascular complications are common and consist of both 
arterial and venous occlusion. These have been reported by a 
number of authors 49 - 54 • 
Arterial complications were present in 34% of 200 patients 
presenting to the Hammersmith Hospital with PV
50
• There were 
39 cerebrovascular, 10 coronary, and 25 peripheral vascular 
events in 68 patients. The peripheral vascular events included 
15 cases of digital artery involvement with sudden onset of 
ischaemia and 10 cases of femoral artery occlusion. Values for 
PCV overall are not given, but the 2 reported cases had 
haemoglobin concentrations of 16.7 and 19.0 g/dL. 
Erythrocytosis is recognised as a risk factor for acute 
arterial occlusion and steps to reduce PCV in the acute surgical 
management of these occlusions are recornrnended
55 • 
Pearson and Wetherley-Mein5
4 described 56 vascular occlusive 
episodes in 69 patients with PV in a period of 332 patient-years. 
These were made up of 28 arterial events: 2 mesenteric, 
4 coronary, 15 cerebral and 7 lower limb; and 28 venous: 18 deep 
vein, 9 superficial vein and 1 retinal vein thromboses. The risk 
,fa vascular occlusive event increased with increasing PCV, 
being 0.2 per 10 years with PCV 0.4 to 0.44, 0.92 with PCV 0.45 
to 0.49, 2.29 with PCV 0.50 to 0.55, 3.33 with PCV 0.55 to 0.59 
and 7.50 with PCV greater than 0.6 L·L-
1 • 
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Arterial complications are thought to be due to reduced flow 
as a consequence of increased whole-blood viscosity~·
53 , although 
PV often has associated thrombocytosis which may exacerbate the 
occlusive tendencies. Arterial occlusion is described in both PV 
and secondary erythrocytosis. 
Venous thrombosis was reported in 28% of the Hammersmith 
group50 • The majority of these were superficial thrombophlebitis 
(30/66 events) and deep vein thrombosis (25/66 events). 
Pulmonary embolism, portal vein, and subclavian vein thrombosis 
were reported in a few instances. Dormandy and Edelman
51 
described a relationship between deep vein thrombosis and 
viscosity. 11/52 patients who developed deep vein thrombosis 
after surgery had 21% higher whole-blood viscosity than those who 
did not. Similar pathogenetic mechanisms to those in arterial 
disease are thought to be responsible. 
1.3.3 Cerebrovascular accidents 
Epidemiologic and post-mortem studies have shown a 
significant increase in the incidence of strokes with increase in 
PCV. Data from the Framingham study56 show that the relative 
risk of a cerebral infarction with haemoglobin concentrations 
greater than 15 g/dL in men and greater than 14 c1/dL in women is 
1.97 times that in individuals with a lower haemoglobin 
concentration. The risk of cerebral infarction was also 
increased with hypertension and smoking. 
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A post-mortem study from Japan
57 showed that the incidence 
of cerebral infarction was 6.6% with PCV less than 0.3 L·L-
1 , 
increasing to 43.6% with PCV between 0.46 and 0.50 L·L-
1 , and 
63.6% with PCV greater than 0.51 L·L-
1 • Other risk factors 
assessed included the severity of atherosclerosis and 
hypertension. Increasingly severe atherosclerosis was additive 
to the effects of PCV, but hypertension did not appear to add to 
the incidence of cerebral infarction. The authors suggested that 
the optimal PCV was between 0.41 and 0.46 L·L-
1 in individuals 
aged under 78 years and between 0.36 and 0.40 L·L-
1 in older 
individuals. 
The incidence of cerebral infarction in patients with 
secondary erythrocytosis is unknown, although anecdotal evidence 
suggests an increased incidence. Rosove et al
34 followed a 
cohort of 40 adult patients with cyanotic congenital heart 
disease for a mean of 5.1 years. Their patients had PCV in the 
range of 0.58 to 0.70 L·L-1 • Five patients died during follow-
up, one of pneumonia and four "suddenly" without a specified 
cause of death. Only three autopsies were obtained and cerebral 
micro-infarction was evident in one. 
1.3.4 Cerebral blood flow 
Other neurological complications are common in 
erythrocytosis58 • These include headache (in up to 60% of 
individuals with erythrocytosis), vertigo (in between 30 and 
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50%), tinnitus (3 to 10%), visual symptoms (10 to 30%) and 
paraesthesiae (10 to 50%). 
There is convincing evidence that cerebral blood flow is 
dependent upon the PCV59 - 64 and that reduction in PCV improves 
cerebral blood flow and abolishes the majority of neurological 






• Thomas et al 59 have 
shown that lowering the PCV from a mean of 0.536 L·L-
1 to 
0.455 L·L-1 increased the cerebral blood flow by 73%. The 
initial mean cerebral blood flow was 37.9, compared to a normal 
value of 69.1 mL·lOOg tissue- 1 ·min-
1 • Subsequent studies by the 






The level to which the PCV should be reduced was addressed 
by Thomas et al59 • They showed that cerebral blood flow was low 
in 17 of 19 subjects with PCV greater than 0.50, but low in only 
2 of 21 subjects with PCV less than 0.46 L·L-
1 • In the range 
0.46 to 0.50 L·L-1 , 14 of 25 had normal and 11 low cerebral blood 
flow. This suggested that the accepted range of PCV during 
venesection programmes (0.47 to 0.50 L·L-
1 ) may be too high for 
optimal cerebral blood f lm,1 and that aiming at lower levels of 
PCV during venesection may be beneficial. 
A contrary view has been proposed on the grounds that the 
brain has inherent vascular regulatory mechanisms to ensure 
adequate oxygen supply62 • The low cerebral blood flow in 
erythrocytosis may be due to increased arterial oxygen content 
and not a consequence of hyperviscosity. Brown and Marshall
64 
studied patients with hyperviscosity due to paraproteinaemia and 
- 23 -
failed to show a correlation between cerebral blood flow and 
viscosity. A group of 7 patients with leukaemia, increased blood 
viscosity and anaemia were shown to have cerebral blood flow 
appropriate to their level of anaemia. Reduction in viscosity by 
plasmapheresis showed a similar lack of correlation between 
viscosity and cerebral blood flow. This was thought to 
demonstrate that regulatory mechanisms maintain normal cerebral 
oxygen transport despite increased plasma or whole blood 
viscosity. 
1.3.5 Cerebral function 
Measurements of cerebral function in erythrocytosis have 
been made to quantify the neurological symptoms experienced. 
Psychometric tests of alertness in 24 patients with PCV greater 
than 0.46 (mean 0.536) L·L-1 demonstrated that a standardised 
score for alertness was considerably lower than that for matched 
controls (-3.3 ± 4.2 compared to 0.0 ± 2.9). Sixteen patients 
underwent venesection to mean PCV 0.479 L·L-
1 with cerebral blood 
flow increasing from 44.3 to 56.9 rnL·lOOg tissue-
1 ·min-1 • The 
alertness score improved by a mean of 2.82 units with good 
correlation between the alertness score and cerebral blood 
f low61 • 
1.4 Pathophysiology 
The effects of erythrocytosis are predominantly due to 




64 • The major determinants of 
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whole-blood viscosity are plasma viscosity, temperature, PCV and 




The PCV is the dominant influence on whole-blood viscosity. 
Begg and Hearns68 showed that the logarithm of whole-blood 
viscosity increased linearly with PCV over the range 0.20 to 
0.60 L·L-1 • 
This can be represented as: 
log(vis) = k + k 1 x H 
Where vis is the whole-blood viscosity, k a constant close to 
plasma viscosity in value, k 1 a constant which varies with shear 
rate and H is PCV 69 
The flow through a tube may be approximated by Poiseuille's 
Law: 
F 1 ow = ( P 1 - P 2 ) x rr x r 4 / ( 8 x L x vis ) 
Where P 1 and P2 are the arterial and venous pressures, r the 
radius of the vessel and L the length. 
From this it can be seen that organ blood flow is inver_9ly 
related to viscosity, as well as being dependent on inherent 
characteristics of the vessels. 
The relationship between PCV and whole-blood viscosity is 
portrayed in figure 1. 370 • 
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Figure 1.3: Plot of whole blood viscosity against increasing PCV 
10 
8 
0 L__ __ __J ____ ____!. ____ __c. _____ ~ 
O 20 40 60 80 
PCV (L/L) 
Redrawn from Wells, Merrill; 1962 
It can be seen that whole-blood viscosity increases in a 
near linear fashion to values of PCV about 0.50 L·L-
1 , followed 




Organ blood flow should therefore fall inversely with 
increase in PCV. There is, however, evidence that there are in 
vivo compensatory mechanisms to overcome the increase in apparent 
peripheral resistance caused by the increased viscosity. These 
include increased cardiac output, increased blood volume, 
vasodilatation and auto-regulation64 • 71 • 
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1.4.2 Oxygen transport 
Oxygen delivery to tissues is dependent upon cardiac output 
(tissue blood flow) and oxygen carriage by the blood. The 
carriage of oxygen in blood depends upon the amount dissolved in 
plasma ( 0. 0225 rnL 0 2 • 100 rnL blood-
1 • kPa P02-1), which is 
insignificant at normal barometric pressures and inspired oxygen 
concentrations, and the amount bound to haemoglobin: 
1.39 X [Hb] X Sa02 rnL/ 100 rnL blood 
where [Hb] is the haemoglobin concentration (g/dL), and Sa02 
the fractional arterial oxygen saturation of haemoglobin
72 • 
Haemoglobin concentration is thus an important determinant of 
tissue oxygen delivery73 , 74 • 
Increasing PCV provides opposing forces for oxygen delivery 
to the tissues. On the one hand, increased PCV increases oxygen 
carriage by increasing haemoglobin concentration; on the other, 
increasing PCV reduces the tissue perfusion by increasing 
viscosity. 
This paradox has been addressed by Castle and Jandl
75 • By 
analysing the effects of increasing PCV on blood flow and oxygen 
carriage, they were able to construct a figure similar to 
figure 1.4. This shows that oxygen transport is reduced at low 
PCV (i.e., anaemia) and increases to an apogee with PCV 
approximately 0.36 to 0.42 L·L-
1 and thereafter oxygen transport 
falls progressively as PCV increases. 
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Figure 1.4: Theoretical analysis of oxygen transport related to PCV 
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This theoretical approach parallels the in vivo findings of 
workers with regard to cerebral blood flow
59 •
60 •
65 and in dogs. 
Richardson and Guyton76 studied anaesthetised dogs in which 
the PCV was manipulated and demonstrated an inverse correlation 
between PCV and cardiac output. Calculation of the number of 
erythrocytes available for oxygen transport showed a maximum when 
the PCV was close to 0.40 L·L-
1 • Similar findings were shown by 
Murray et al77 who demonstrated that oxygen transport was normal 




The aims of management in erythrocytosis, of whatever 
aetiology, are to control the underlying disease and to reduce 
the effects of erythrocytosis on organ function. Other 
therapeutic manoeuvres may be required in PV to control other 
manifestations of the myeloproliferation. The available 
therapeutic manoeuvres for control of erythrocytosis include 
venesection and chemotherapy ( in PV) 
16 ,43 ,44 ,78 . 
Venesection is the controlled removal of aliquots of red 
cells either by physical removal of whole blood, with or without 
volume replacement, or by apheretic techniques with the removal 
of red cells while plasma is returned to the patient. 
1.5.1 Aims 
The aims of venesection are to reduce the PCV and hence the 
whole-blood viscosity to improve tissue perfusion and hence 
oxygen delivery. This has been shown to improve cerebral blood 
f low59 •60 •65 ·66 , improve symptoms
61 · 79 ·80 and to allow resolution of a 
number of vascular occlusive episodes
54 ·55 ·81 . Other benefits, 
which are more likely to occur in erythrocytosis secondary to 
hypoxic lung iisease include reductions in pulmonary vascular 
resistance and pulmonary pressures and possible improvement in 
exercise capaci ty3,33,34, 45, 79-81. 
The extent of venesection needs to balance the improvement 
in tissue perfusion induced by reduced viscosity against the 
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reduced oxygen carriage caused by the reduction in haemoglobin 
concentration. The extent to which the PCV must be lowered has 
not been clearly established. 
1.5.2 Complications 
Venesection is not without its hazards. The acute 
complications described following venesection include acute 
vascular events due to thrombotic occlusion of vessels, marked 
drop in circulating blood volume with hypotension and 
collapse55 •82 • More chronic complications may arise following 
venesection with the removal of oxygen-carrying capacity and 
reduced tissue oxygen delivery and ischaemia. Serial venesection 
results in iron deficiency, which may produce increased viscosity 
in its own right, or be associated with the development of other 
symptoms related to the iron deficiency. 
1.5.2.1 Vascular events 
Rapid removal of blood volume by venesection, without 
adequate volume replacement, has been documented to cause a 
significant number of problems 55 •82 • These seem to arise 
particularly in the elderly and in patients with significant 
cardiovascular disease. Events described include myocardial 
infarction, collapse, convulsions and acute renal failure. ~he 
postulated mechanism for this is the relatively slow replacement 
of intravascular volume with fall in cardiac output in the face 
of sustained PCV and viscosity. This may result in stasis or 
thrombosis. Caution during venesection is necessary, although 
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the hazards may be reduced by balanced infusion of normal saline 
or dextran to block the effects of reactive thrombocytosis
55
• 
1.5.2.2 Oxygen carrying capacity 
Reduction in oxygen-carrying capacity is more likely to 
produce problems in patients with erythrocytosis secondary to 
hypoxic lung disease or cyanotic congenital heart disease. 
Oxygen delivery to tissues is composed of oxygen carrying 
capacity (i.e. oxygen transported bound to haemoglobin) and 
tissue perfusion. As has been shown previously, venesection and 
reduction in PCV results in improved tissue perfusion and the 
benefit of this has to be balanced against the reduced oxygen 
carriage. 
The evidence for improved cerebral blood flow and pulmonary 
haemodynamics after venesection has been presented. Measurement 
of regional blood flow in other organs conforms to these 
findings. Resting calf blood flow was unchanged after 
venesection PCV 0.61 to 0.51 L·L-
1 , however peak calf blood flow 
during reactive hyperaemia was increased by 17% at one and 21% at 
seven days after venesection. Calculated oxygen transport was 
reduced by 20% at rest, but unchanged during reactive 
hyperaemia00 • This confirms that improved rec:onal ~issue 
perfusion compensates for decreased oxygen carrying capacity. 
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1.5.2.3 Fe deficiency 
Iron deficiency is a consequence of repeated venesection and 
may be a desirable result as this will reduce erythropoiesis and 
thus increase time between venesections. Whole blood viscosity 
has been shown to increase as erythrocyte size falls
70 • This may 
be due to decreased deformability of erythrocytes which is 
necessary for passage through capillaries. Hutton
83 showed that 
whole blood viscosity increased in erythrocytotic patients 
treated by venesection. This has led to the recommendation that 
iron deficiency be prevented during venesection for 
erythrocytosis. Subsequent studiesM-~ have shown that whole 
blood viscosity was unchanged whether iron-deficient or replete 
at comparable PCV. In patients with erythrocytosis secondary to 
hypoxia, however, oxygen transport has been shown to be decreased 
by 11% at a constant PCV of 0.50 L·L-
1 when mean corpuscular 
haemoglobin fell from 30 to 20 pg as a consequence of iron 
deficiency85 • 
Iron deficiency is thus desirable in PV, but may be 
deleterious in secondary erythrocytosis when oxygen transport is 
paramount. 
Patients with erythrocytc~is secondary to cyanotic 
congenital heart disease have been shown to fall into two 
groups 34 • 35 • One group maintains a stable elevated PCV with very 
few symptoms, whereas the other requires frequent venesections to 
maintain a stable PCV. The latter group frequently develops 
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symptoms of hyperviscosity, which are associated with iron 
deficiency, so-called "decompensated erythrocytosis". Correction 
of the iron-deficient state results in rapid increase in PCV and 
hyperviscosity34 • 
1.6 Optimal level of PCV 
A controversy in the management of erythrocytosis by 
venesection revolves around the level of PCV to which venesection 
should be conducted. The PCV for optimal function has neither 
been established in individuals with erythrocytosis secondary to 
hypoxia, nor in those with erythrocytosis which is primary (PV) 
or secondary to some other process, but in the presence of normal 
cardiac and respiratory function. 
Common-sense, and accepted practice, suggest that returning 
the PCV to near the normal range of approximately 0.42 to 
0.47 L·L-1 is adequate. There is certainly evidence that levels 
of PCV greater than 0.55 L·L-1 are associated with unacceptably 
high viscosity, markedly reduced cerebral blood flow and a large 
increase in the incidence of complications due to erythrocytosis. 
The studies of Weisse et al4 in patients with hypoxic lung 
disease suggested that reducing the PCV to approximately 
0.50 L·L- 1 was beneficial in terms of haernodynarnic function and 
that levels lower than this did not produce further haemodynarnic 
improvement. 
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There is, however, a considerable body of evidence which 
suggests that the frequently accepted target for venesection of 
between 0.45 and 0.50 L·L-1
 is suboptimal. This evidence 
includes the data cited from the Framingham study
56 and other 
epidemiogic investigations demonstrating increased vascular, 
particularly cerebrovascular, morbidity with PCV greater than 
0.40 L·L-1 • Cerebral blood flow studies have shown similar 
trends with improved cerebral blood flow found when the PCV is 
between 0.40 and 0.45 L·L-1 • Theoretical and other experimental 
analyses have similarly suggested that the optimal combination of 
haemoglobin and cardiac output in terms of oxygen transport is 
found when the PCV lies between approximately 0.36 and 
0.44 L·L-1 • 
There are no studies which have prospectively examined the 
functional effects of systematically reducing the PCV from high 
levels to low normal levels in the region of 0.40 L·L-
1 in 
patients in whom effects of cardiac or pulmonary disease can be 
dissociated from the effects of erythrocytosis. 
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Chapter 2 
Objectives and hypothesis 
The aim of the study was to prospectively investigate the 
effects of a graded venesection programme on individuals with 
erythrocytosis. This was to attempt to define the optimal PCV 
that would enable patients to function as normally as possible. 
The hypothesis was that graded venesection to PCV levels of 
0.50 L·L-1 , and then 0.40 L·L- 1 in patients with erythrocytosis, 
but no significant cardiac or respiratory disease, would result 
in improved function. This was to be judged on the grounds of 
clinical, haematological, rheological, pulmonary function, 
exercise and cerebral blood flow changes. 
The discussion in the previous chapter has shown evidence 
that erythrocytosis is deleterious in terms of organ perfusion 
and oxygen transport. Procedures to measure these variables 
include cerebral or calf blood flow and exercise testing. 
Cerebral, and other organ, blood flow studies measure perfusion, 
but not necessarily oxygen delivery. The effects of impaired 
perfusion and oxygen delivery are most likely to be evident when 
organ function is stressed. Exercise poses an easy stress to 
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administer, but may be affected by confounding factors such as 
impaired cardiovascular or respiratory responses. 
The management of relative erythrocytosis is completely 
different to that of absolute erythrocytosis14 • The study was 
thus aimed at investigating individuals with absolute 
erythrocytosis only. 
Entry into this study was restricted to individuals with 
absolute erythrocytosis but normal or near normal cardiac and 
respiratory function to allow us to use exercise testing as an 
objective measure of tissue perfusion and oxygen delivery. 
Exercise responses in individuals with respiratory or 
cardiac disease are likely to be affected by the disease process 
as well as by the erythrocytosis. While these patients pose an 
important clinical group, we felt that the problems of 
erythrocytosis in them should be addressed once the hypotheses 
had been addressed in less compromised individuals. We felt that 
results from individuals with erythrocytosis, but no other 
significant disease, could provide pointers for further studies, 
but that the results from this selected group of patients could 
not be extrapolated to patients with erythrocytosis as a whole 




3.1 Criteria for enrolment 
Requirements for inclusion in the study were that the 
patients should have absolute erythrocytosis with near normal 
cardio-respiratory function. PCV at presentation had to be 
greater than 0.55 L·L-1 and red cell mass equal to or greater 
than 3 8 rnL • kg-1 • 
Screening assessment was by history, physical examination, 
electrocardiograph, chest X-ray, spirometry, full lung volumes, 
single breath diffusing capacity, full blood count and 
measurement of red cell mass and plasma volume. 
Because exercise was to be a maJor part of the study, 
individuals who were unable to perform cycle ergometry for 
reasons of physical deformity or disabling peripheral vascular 
disease were not considered for enrolment. For the ~~me reason, 
patients who did not have normal or near normal lung function and 
clinically normal cardiovascular systems, apart from controlled 
hypertension, were not enrolled. 
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The study was approved by the Ethics and Research Committee 
of the University of Cape Town and Groote Schuur Hospital. 
Subjects gave informed consent before participating in the study. 
3.2 Procedure 
The study was designed so that patients would act as their 
own controls. Each subject was fully investigated on three 
occasions. The first set of studies were done at presentation. 
The studies were repeated after controlled venesection to a 
target PCV of 0.50 L·L-1 , and then again when the PCV was 
0.4 L·L-1 • 
After the initial studies, patients were seen at weekly 
intervals in the Haematology Clinic at which time their PCV was 
reduced by 300-500 mL venesections. They were restudied after 
the PCV had been stabilised at each of the two target levels for 
at least one week. 
Patients were encouraged to continue normal activities 
during the study period with no restrictions placed upon diet or 
exercise, although beginning a formal exercise programme was 
discouraged. 
Once the PCV had been stabilised at the target value, 
patients underwent the series of investigations. Patients came 
to the hospital in the morning after an overnight fast, at which 
time blood for haematological and biochemical analyses were 
drawn. They then reported to the Respiratory Clinic laboratories 
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for pulmonary function testing, followed by incremental and 
steady state exercise testing. Cerebral blood flow studies were 
usually done on the following morning. 
3.3 Clinical evaluation 
Prior to each testing session the patients were clinically 
evaluated by history and physical examination. Particular 
emphasis was placed on symptoms such as headache, early morning 
confusion or "thick-headedness", ability to concentrate and 
vascular complications. Examination was aimed at the 
cardiovascular and central nervous systems to evaluate the 
effects of decreasing PCV on perfusion, known vascular 
complications and haemodynamic function. 
3.4 Haematology 
Haematological studies included full blood count (Coulter 
Counter S-Plus, Coulter Electronics, Hialeah, Florida, USA) 
measuring haemoglobin concentration, red cell indices such as 
mean corpuscular volume (MCV), and white cell and platelet 
counts. PCV was measured in duplicate by the capillary technique 
using a calibrated microcent~ifuge and standardised reader 
(Hawksley, England). Whole blood viscosity was measured using 
the Brookes-Wellfield cone and plate rheometer (Brookfield 
Engineering Laboratories, Stroughton, Massachusetts, USA). Red 
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cell volume was measured using a chromium-labelled red cell 
technique15 • 
3.5 Pulmonary function testing 
Lung volumes were determined using a water-sealed spirometer 
(Expirograph, Godart-Statham, Bilthoven, Holland) with 
measurement of functional residual capacity by helium dilution. 
Diffusing capacity for carbon monoxide was estimated by the 
single breath technique (Transfer Test, PK Morgan, Chatham, Kent, 
UK). Criteria of the American Thoracic Society
87 for 
reproducibility of spirometric variables were applied. Reference 
values for volumes, spirometry and diffusing capacity were those 
validated for use in our laboratory88- 90 • 
3.6 Cerebral blood flow 
Cerebral blood flow was determined using a 133Xe wash-out 
technique91 , in which patients rebreathed a gas mixture 
containing oxygen and .133Xe while maintaining a constant end-tidal 
carbon dioxide tension. Clearance curves were then obtained over 
each cerebral hemisphere and values for blood flow in the fast 
clearing tissue, p redominantly grey matter, derived by computer. 
The mean of left and right hemispheral blood flow (normal range 
>50 mL·lOOg tissue-1 ) was taken. 
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3.7 Exercise testing 
3.7.1 Incremental protocol 
Incremental exercise testing was carried out by means of the 
"Stage 1" test described by Jones92 • This involved cycle 
ergometry (Monark 668, Vyborg, Sweden) with workload increments 
of 100 kilopond·metres·minute-1 (kp·m·min-1 ). 
The subject came to the exercise laboratory and changed into 
appropriate clothing, following which electrodes were placed in a 
modified CM5 configuration for heart rate monitoring. After an 
initial period of resting measurement, the subject pedalled the 
ergometer at a cadence of 50 rpm, in time with a metronome. The 
workload was increased by 100 kp·m·min-1 every minute until the 
subject could no longer maintain the required cadence. 
Measurements made included heart rate, ventilation (dry gas 
meter; Parkinson-Cowan CD4, Manchester, UK), blood pressure, 
end-tidal PC02 (infra-red CO2 analyser; Mk 901/2, PK Morgan, 
Chatham, Kent, UK) and arterial oxygen saturation (HP47201A, 
Hewlett-Packard, Palo Alto, California, USA). 
Outputs from the electrocardiograph, dry gas meter and gas 
analysers were recorded on a chart recorder (Mingograf 82, 
Siemens-Elema, Sweden). Results were calculated off-line using 
standard formulae 92 • The data were entered into a personal 
computer (Tektronix 4052, Beaverton, Oregon, USA) and plotted 
(Tektronix 4662) using a custom-written BASIC program. 
- 41 -
Maximum workload achieved, heart rate and ventilation were 
compared to standard predicted values (see appendix 1 for 
details). The "ventilatory turnpoint" was determined by 
inspection of the plot of minute ventilation against workload93 • 
3.7.2 Steady state protocol 
Steady state measurements (Jones' "Stage 2/3"~) were made 
to accurately calculate gas exchange and cardiac output. 
Recordings were made at rest and during steady state exercise at 
a workload of 30% of the maximum workload achieved during the 
incremental exercise test. Steady state was determined after at 
least 3 minutes of exercise by the presence of stable mixed 
expired gas fractions and heart rate fluctuation of less than 
5 beats· min-1 over a 30 s period. 
Mixed expired oxygen (Model S3A oxygen analyser, Applied 
Electrochemistry, Sunnyvale, California, USA) and carbon dioxide 
fractions were measured from a 15 L expired gas mixing chamber. 
Blood gases and pH were measured using arterialised capillary 
ear-lobe blood sampling (ABL2, Radiometer, Copenhagen, Denmark). 
Cardiac output was measured by the indirect Fick method using an 
equilibrium carbon dioxide rebreathing techniqueM,%. Outputs 
were recorded on the chart recorder as in "Stage l" test .. · ng and 
results calculated using standard forrnulae92 , which are outlined 
in appendix 2. 
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3.8 Statistics 
Results obtained from each level of PCV were compared by 
one-way analysis of variance, using the Scheffe technique to test 






Nine patients with PCV greater than 0.55 L·L-1 were 
enrolled. Four had polycythaemia vera (PV), diagnosed using 
standard criteria13 and 5 had erythrocytosis presumed secondary 
to smoking~·~, the diagnosis being made on a history of current 
heavy smoking when other possible causes of erythrocytosis had 
been excluded21 • Basic demographic data at presentation are 
shown in table 4.1. 
The patients presented to the Department of Haematology or 
Respiratory Clinic in a variety of ways (table 4.1). Four were 
found to have erythrocytosis on routine testing following 
presentation with unrelated complaints. The remaining 5 were 
diagnosed as having erythrocytosis after presenting with symptoms 
or signs related to erythrocytosis. 
Those with occlusive vascular disease had their presenting 
problem controlled by the referring surgeons or physicians, but 
did not receive any specific therapy for the erythrocytosis prior 
to enrolment in the study. The patients with PV did not receive 
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therapy other than phlebotomy during the study period. Patients 
with erythrocytosis secondary to smoking ceased to smoke during 
the study. No patient was receiving a drug which could influence 
exercise performance. 
Table 4.1: Patient data at presentation 
Patient Sex Age Ht Wt Diag Smoke Reason for presentation 
yr cm kg pk·yr 
1 F 60 162 55 PV 0 Ischaemic toes 
2 M 43 172 88 PV 0 Vertigo, pruritus 
3 M 51 180 77 PV 0 Diabetes, routine FBC 
4 M 57 173 59 PV 10 Routine examination 
5 M 40 158 48 Sm 10 Acute arterial occlusion 
6 M 32 192 83 Sm 30 Deep venous thrombosis 
7 M 34 166 46 Sm 25 Hypertension, routine FBC 
8 M 39 169 60 Sm 20 Back pain, routine exam 
9 M 39 180 74 Sm 20 Investigated for narcolepsy 
Sm: Erythrocytosis secondary to smoking; pk·yr: pack·years 
Two subjects were studied at presentation and after 
venesec~ ion to PCV of 0.5 L·L-1 only. Patient 8 withdrew because 
of problems related to the time needed off work to attend for the 
regular venesection sessions. Patient 9 was withdrawn when the 
diagnosis of narcolepsy was made and he was started on 
methylphenidate as it was thought that this may influence the 
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outcome of exercise testing. Neither patient had suffered any 
adverse effects during the period of venesection. 
4.2 Clinical evaluation 
All subjects had near normal clinical examinations at 
presentation, with abnormal features being those directly 
attributable to erythrocytosis. All had symptoms suggestive of 
expanded red cell mass including lethargy, early morning headache 
and mental clouding. Physical signs included plethora, 
peripheral cyanosis, and impaired capillary filling in most, and 
evidence of mild peripheral vascular disease in 2 patients. 
There were no signs of cardiac decompensation or disabling 
vascular disease. 
Chest radiographs were essentially normal, apart from rather 
plethoric lung fields and mild hyperinflation in some cases. 
Electrocardiographs were similarly within normal limits, apart 
from left ventricular hypertrophy in a patient with controlled 
systemic hypertension. 
Repeat clinical evaluation at a PCV of 0.5 L·L-1 and 
subsequently at 0.4 L·L-1 demonstrated an improvement in well-
~ being and activity levels and a marked diminution of symptom~ in 
all subjects. Peripheral circulatory problems were uniformly 
resolved. These clinical features had begun to improve by the 
time PCV reached 0.5 L·L-1 and had improved further when the PCV 
was 0.4 L·L-1 • Four subjects were reassessed one month after 
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completion of the study, during which time they had been 
maintained at a PCV of 0.4 L·L-1 and each demonstrated further 
improvement in subjective well-being. 
No adverse effects of venesection were apparent and there 
were no acute vascular occlusive events or episodes of 
hypotension during the venesection programme. 
4.3 Haematologic studies 
At presentation, all subjects had elevated PCV in the range 
0.56 to 0.70 L·L-1 (table 4.2). The haemoglobin concentrations 
were elevated in the range 182 to 234 g·L-1 • White cell counts 
were normal in the 5 subjects with erythrocytosis secondary to 
smoking and were mildly elevated (19.0 to 25.9 x 109 ·L-1 ) in 3 of 
those with PV. Platelet counts were similarly normal in smokers 
and elevated (524 to 1093 X 109 ·L-1 ) in 3 of the patients with PV. 
Mean corpuscular volumes at presentation were in the range 
78 to 102 (92.7 ± 13.3; mean± sd) fL. Serum vitamin B12 and 
serum and red cell folate levels were normal. Iron stores as 
reflected by serum iron, total iron binding capacity, percentage 
saturation of transferrin and ferritin levels were normal. 
Red cell mass and plasma volume estimations confirmed the 
presence of absolute erythrocytosis, with red cell mass at 
presentation in the range 38 to 67 rnL·kg-1 (table 4.2). In 2 
cases measurement of red cell mass could not be performed because 
of the need to intervene with urgent treatment of the 
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erythrocytosis. Both of these patients had PV and thus 
unequivocal absolute erythrocytosis. 
Table 4.2: Haematologic data at presentation 
Patient Hb PeV wee Pl MeV ReM 
g ·L-1 L·L-1 x109 ·L-1 x109 ·L-1 fL mL· kg-1 
1 207 0.67 19.3 552 78.5 
2 184 0.58 16.6 797 88.1 38 
3 234 0.70 10.3 352 80.7 67 
4 210 0.66 19.1 901 72.1 
5 182 0.56 6.8 115 102.0 38 
6 211 0.60 6.2 286 111.0 44 
7 194 0.59 9.1 231 102.0 52 
8 190 0.56 7.1 202 101. 0 38 
9 189 0.58 7.1 199 99.0 38 
Mean 200 0.61 11. 3 404 92.7 
sd 17 0.05 5.5 282 13.3 
wee: White cell count; Pl: Platelet count; ReM; red cell mass; PlV: plasma volume 
PlV 








The venesection programme resulted in achievement of the 
target PeV for each subsequent period of testing. This fall in 
PeV was associated with an appropriate fall in haemoglobin. 
Haemoglobin concentration was 200 ± 17 g·L-1 at presentation, 
162 ± 6 g·L-1 at Pev of 0.5 L·L-1 (p<0.001 compared to 
presentation, table 4.3), and fell to 129 ± 8 g·L-1 at a Pev of 
0.4 L·L-1 (p<0.0001 compared to presentation, table 4.4). 
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The mean wee remained unchanged throughout the study period. 
The platelet count increased following venesection in 3 of the 4 
patients with PV. This increase was particularly marked at the 
pev level of 0.4 L·L-1 • The platelet count in subjects 2 and 4 
increased markedly with presentation counts of 797 and 
901 x109 ·L-1 increasing to 1760 and 1960 x109 ·L-1 respectively by 
the third study day. No untoward sequelae of these 
thrombocytoses occurred. Platelet counts in patients with 
smoking-induced erythrocytosis remained in the normal range. 
Mean corpuscular volume tended to fall during the 
venesection programme from 92.7 ± 13.3 at presentation to 
84.2 ± 16.6 fL when the Pev was 0.4 L·L-1 • In three patients (2, 
3, and 4) the Mev fell markedly to between 65.2 and 72.1 fL. 
Iron studies were initially normal in all cases and repeat 
studies showed the development of marked iron deficiency in these 
patients. Ferritin values fell to between 10 and 15 ng·mL-
1 • 
Iron studies were unfortunately not performed on all patients 
during the follow-up studies. 
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Table 4.3: Haematologic data on second study day 
Patient Hb PeV wee Pl MeV 
g. L-1 L·L-1 xl09 ·L-1 xl09·L-1 fL 
1 160 0.51 6.0 522 81. 0 
2 158 0.48 25.3 754 76.1 
3 157 0.50 12.6 513 72.0 
4 157 0.50 21. 3 1090 71.5 
5 164 0.50 6.5 150 97.0 
6 166 0.52 4.7 163 107.0 
7 158 0.48 5.5 360 101. 0 
8 171 0.50 5.4 248 101. 0 
9 170 0.50 10.7 218 98.7 
Mean 162 0.50 10.9 446 89.5 
sd 6 0.01 7.6 313 14.1 
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Table 4.4: Haematologic data on third study day 
Patient Hb PeV wee Pl MeV 
g. L-1 L·L-1 x109 ·L-1 xl09 ·L-1 fL 
1 117 0.36 4.1 309 82.2 
2 128 0.40 25.0 1760 65.2 
3 122 0.38 14.3 705 68.2 
4 131 0.42 9.9 1960 72.1 
5 137 0.40 6.3 293 96.6 
6 140 0.42 5.0 395 107.0 
7 126 0.39 6.5 271 98.4 
Mean 129 0.40 10.2 813 84.2 
sd 8 0.02 7.4 732 16.6 
Whole blood viscosity was markedly elevated at 10.7 ± 3.3 cP 
at presentation (normal range 4.9 to 6.9 cP, measured at a shear 
stress of 100 s-1). Following venesection, whole blood viscosity 
fell to 8.0 ± 1.1 when measured at a Pev of 0.5 L·L-1 (p<0.05 
compared to presentation) with a further fall at Pev of 0.4 L·L-1 
to 6.2 ± 0.8 (p<0.005 compared to presentation, and p<0.05 
compared to Pev 0.5). This is seen in table 4.5 and figure 4.1 
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Table 4.5: Whole blood viscosity 
Patient Initial PCV=0.5 PCV=0.4 
cP cP cP 
1 13.8 6.1 6.1 
2 8.5 8.4 7.1 
3 17.2 9.4 5.5 
4 8.9 9.7 6.8 
5 8.1 7.5 4.9 
6 8.5 7.6 6.0 
7 7.4 7.4 6.9 
8 12.9 8.2 
9 10.8 7.3 
Mean 10.7 8.0 6.2 
sd 3.3 1.1 0.8 
p (Init vs 0.5) <0.05 
(0.5 vs 0.4) <0.05 




















p < 0.05 (Pres vs 0.5) 
p < 0.05 (0.5 vs 0.4) 
p < 0.005 (Pres vs 0.4) 
I I 
PCV • 0.5 PCV • 0.4 
Figure 4.1: Plot of whole blood viscosity against PCV 
4.4 Pulmonary function testing 
All subjects had measurement of lung volumes and mechanics. 
These were compared to refE;.i~ence values currently used in the 
pulmonary function laboratory~.M. The data obtained at 
presentation are shown in table 4.6. Patient 5 had moderate 
airflow obstruction, but this was thought to be insufficient to 
account for his erythrocytosis and was unlikely to significantly 
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affect his exercise capacity. Repeat volumes and mechanics on 
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Arterial blood gases were in the normal range at 
presentation, and whenever measured during the study period. 
Arterial oxygen saturations were above 92% in all cases 
(table 4.7). 
Table 4.7: Arterial Pa02 and Sa02 on study days 
Presentation PCV = 0.5 PCV = 0.4 
Patient Pa02 sao2 Pa02 sao2 Pa02 sao2 
kPa % kPa % kPa % 
1 12.8 98 13.9 98 12.3 97 
2 10.9 97 11. 7 97 9.5 92 
3 12.0 96 12.5 97 12.3 96 
4 12.4 96 10.8 95 10.9 96 
5 12.4 96 10.3 96 15.5 98 
6 14.8 98 13.7 98 12.4 97 
7 12.2 95 12.8 98 13.9 98 
8 11. 8 97 12.1 97 
9 11. 9 97 13.6 98 
Mean 12.4 96 12.2 97 12.4 96 
sd 1.1 2 1.3 1 1.9 2 
4.4.1 Diffusing capacity 
Diffusing capacity for carbon monoxide (T 1Cb5b) was markedly 
increased at presentation in all but one patient. T1C05 b was 
123.4 ± 21.2% and transfer coefficient (KCO) similarly increased 
at 128.0 ± 27.4% of the predicted value90 (table 4.8). At PCV 
0.5 L·L-1 both had fallen, to 97.8 ± 8.2% and 101.6 ± 16.6% 
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respectively (table 4.9). There was a further but smaller fall 
when the PCV was reduced to 0.4 L·L-1 (table 4.10). 
Table 4.8: Diffusing capacity at presentation 
Patient T1COsb % pred KCO % pred 
ml· mmHg-1 • min-1 ml· mmHg-1 • min-1 • L -1 
1 31.4 142.1 7.7 156.2 
2 33.5 112.4 6.0 122.4 
3 42.2 137.0 7.6 165.2 
4 40.1 147.4 7.0 159.1 
5 22.3 86.1 4.9 98.0 
6 51.1 132.4 6.1 113.5 
7 39.0 139.8 7.3 137.7 
8 33.2 112.2 5.2 103.6 
9 33.5 101.5 4.9 96.2 
Mean 36.3 123.4 6.3 128.0 
SD 8.1 21. 2 1.1 27.4 
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Table 4.9: Diffusing capacity with PCV 0.5 
Patient T1COsb % pred KCO % pred 
ml· mmHg-1 • min-1 ml· mmHg-1 • min-1 • L-1 
1 23.5 106.3 5.5 110.5 
2 30.6 102.7 6.1 124.2 
3 32.4 105.2 5.6 122.2 
4 24.9 91.5 4.8 109.1 
5 21. 9 84.6 4.7 94.0 
6 38.2 99.1 5.0 93.8 
7 29.7 106.5 5.4 101. 9 
8 28.4 95.9 4.2 83.l 
9 29.2 88.5 3.8 75.9 
Mean 28.8 97.8 5.0 101. 6 
SD 5.0 8.2 0.7 16.6 
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Table 4.10: Diffusing capacity at PCV 0.4 
Patient T1COsb % pred KCO % pred 
ml· rnrnHg-1 • min-1 ml· rnrnHg-1 • min-1 • L-1 
1 19.4 87.8 4.7 95.3 
2 27.8 93.3 5.4 110.0 
3 30.6 99.4 5.4 117.2 
4 20.5 75.4 3.4 76.8 
5 18.4 71. 0 4.2 83.2 
6 35.0 90.8 4.6 86.3 
7 26.2 93.9 5.1 96.2 
Mean 25.4 87.4 4.7 95.0 
SD 6.3 10.4 0.7 14.5 
Diffusing capacity fell more markedly relative to the change 
in haemoglobin concentration when venesection reduced PCV from 
presenting values to 0.5 L·L-1 than when PCV was reduced from 0.5 
to 0.4 L·L-1 • This is shown in figure 4.2. There was a 
significant correlation between change in T1COsb and change in 
haemoglobin concentration when PCV was decreased from presenting 
values to 0.5 L·L-1 (figure 4.3, r = 0.72, p = 0.03), but no 
correlation between changes in T1COsb and haemoglobin when PCV was 
reduced from 0.5 to 0.4 L·L-1 (figure 4.4, r = -0.05, p = 0.92). 
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Figure 4.2: Diffusing capacity as percentage predicted, compared 
to haemoglobin at presentation and following venesection 
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Figure 4.3: Diffusing capacity change between presentation and PCV o • .r 
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Figure 4.4: Diffusing capacity change between PCV 0.5 and 0.4 
4.5 Cerebral blood flow 
Cerebral blood flow could not be measured in one patient 
because of technical difficulties, but was measured on the day 
following exercise and pulmonary function testing in all other 
patients. CBF was below the normal value of 50 rnL·min-1 ·(100g 
tissue)-1 in 7 of the 8 patients at presentation with mean CBF 
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being 39.8 ± 5.3 (table 4.11). There was a moderate increase in 
CBF to 47.9 ± 9.5 following venesection to a PCV of 0.5 L·L-1 • 
At PCV 0.4 L·L-1 CBF was within the normal range in 7 of 8 
patients with mean CBF 58.2 ± 14.2 mL·min-1 ·(100g tissue)-1 
(p <0.001 compared to presenting values). The differences in CBF 
between presentation and PCV O. 5 L • L-1 and PCV O. 5 and O. 4 L • L-1 
were not significant however. 












p (Init VS 
Initial PCV=0.5 PCV=0.4 
mL · min- 1 • ( 100g tissue )-1 
35.5 52.5 57.0 
46.7 49.0 89.1 
36.0 57.9 56.4 
33.3 33.3 49.2 
42.5 50.6 57.5 
35.6 37.4 48.0 
42.2 41. 9 50.0 
46.4 59.7 
39.8 47.9 58.2 
5.3 9.5 14.2 
0.5) NS 
(0.5 vs 0.4) NS 
(Init vs 0.4) <0.001 
-; 
Cerebral blood flow correlated inversely with whole blood 
viscosity (figure 4.5, r = -0.45, p = 0.03). There was a similar 
significant inverse relationship between cerebral blood flow and 
arterial oxygen content, see figure 4.6 (r = -0.66, p = 0.0006). 
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Figure 4.7 shows that there was no correlation between whole 
blood viscosity and cerebral oxygen transport, calculated as the 
product of cerebral blood flow and arterial oxygen content. 
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Figure 4.5: Relationship between whole blood viscosity and 
cerebral blood flow 
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Figure 4.6: Arterial oxygen content and cerebral blood flow 
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Figure 4.7: Calculated cerebral oxygen transport and whole blood 
viscosity 
4.6 Exercise testing 
4.6.1 Incremental exercise 
All subjects were able to exercise on the study day. During 
incremental exercise all subjects were limited by leg fatigue and 
not dyspnoea or other symptoms. Maximum exercise capacity at 
pre sentation was 79.7 ± 22.3 % of predicted92 , which was mildly 
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reduced (table 4.12). Heart rate at maximum exercise was close 
to age-predicted maximum96 in all except patient 3. Only two 
patients reached their ventilatory limit, but neither complained 
of dyspnoea terminating exercise. Heart rate and blood pressure 
responses to exercise were normal. Overall, the ventilatory 
turnpoint was lower than the expected values (60 to 75% of 
maximum exercise). 
Table 4.12: Incremental exercise at presentation 
Patient Workload Heart rate Ventilation Vent TP 
(% pred) (% pred) (% pred) (% max ex) 
1 117 91 73 55 
2 100 102 129 40 
3 64 68 54 60 
4 92 90 45 50 
5 94 96 97 62 
6 50 84 40 62 
7 67 88 60 50 
8 57 97 78 65 
9 77 86 51 65 
mean 79.7 89.0 69.7 56.6 
sd 22.3 9.7 28.6 8.5 
Vent TP: Venti latory tu r npoint; % pred: % predicted maximum; % max ex: % maxi . um exerci se 
There was no significant change in maximum exercise capacity 
following venesection (figure 4.8a), although there was some 
individual variability. Overall maximum exercise capacity was 
78.3 ± 14.3% of predicted at PCV 0.5 L·L-1 (table 4.13) and 
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76.4 ± 23.9% at PCV 0.4 L·L-1 (table 4.14). All patients 
reported that exercise felt easier, although no formal evaluation 
of perceived exertion was done. Similarly, there was no 
significant difference between heart rate at maximum exercise or 
maximum ventilation between presentation and PCV of 0.5 and 
O • 4 L · L -i (Figure 4. Sb and 4. Sc ) . 
The ventilatory turnpoint increased from 56.6 ± 8.5% of 
' t t t ' t 6 8 8 + 10. 8 at PCV O. 5 L • L-1 maximum exercise a presen a ion o • -
(p<0.05 compared to presentation) and 72.6 ± 11.5% at PCV 
0.4 L·L-1 (p<0.01 compared to presentation) (Figure 4.Sd). 
Table 4.13: Incremental exercise, PCV = 0.5 L·L-1 
Patient Workload Heart rate Ventilation Vent TP 
(% pred) (% pred) (% pred) (% max ex) 
1 83 88 78 60 
2 92 104 129 65 
3 64 63 56 70 
4 92 80 45 66 
5 71 101 90 50 
6 56 79 43 78 
7 67 90 57 65 
8 95 103 70 85 
9 85 96 51 80 
mean 78.3 89.4 68.7 68.8 
sd 14.3 13.5 27.4 10.8 
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Table 4 .14: Incremental exercise, PCV O. 4 L · L-1 
Patient Workload Heart rate Ventilation Vent TP 
(% pred) (% pred) (% pred) (% max ex) 
1 100 94 80 70 
2 92 102 131 50 
3 64 65 59 70 
4 108 91 66 75 
5 71 91 89 83 
6 56 84 43 85 
7 44 88 40 75 
mean 76.4 87.6 72.6 72.6 
sd 23.9 11.5 31.2 11.5 
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* p<0.05 
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Initial PCV 0.5 PCV 0.4 
Figure 4.8: Incremental exercise testing data 
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4.6.2 Steady state exercise 
Measurements were made during steady state at rest and while 
exercising at approximately 30% of the maximum workload achieved 
on the preceding incremental test. The workloads during exercise 
ranged from 100 to 400 kp·m·min-1 , and most subjects exercised at 
the same workload on each occasion. The workload during exercise 
when PCV was 0.4 L·L-1 was slightly, but not significantly, 
reduced compared to initial exercise. Resting and exercise 
oxygen consumption were not different as the PCV fell (table 
4.15). Heart rate during exercise was slightly lower when PCV 
was 0.4 L·L-1 than at presentation or when PCV was 0.5 L·L-1 • 
This difference was not significant. There was a similar small 
fall in cardiac output during exercise and a small increase in 
arterial-mixed venous oxygen content difference (table 4.15). 
Blood gas and pH measurements showed a trend for less fall 
in pH and bicarbonate during exercise after venesection. These 
differences were small, however. 
There were no changes in other measures of gas exchange such 







































































































































































































































































































































































































































































































































































































































































































































In response to venesection, all the subjects in this study 
experienced a striking subjective improvement in that they were 
better able to perform day-to-day tasks, had an increase in 
exercise tolerance and mental alertness, diminution in lethargy 
and abolition of headache. This improvement in symptoms was 
marked by the time their PCV reached 0.5 L·L-1 and further 
improvement was evident once stabilisation had occurred at 
0.4 L·L-1 • These observations were supported by clinical 
objective evidence of better tissue perfusion, with marked 
improvement in pre-existing signs of peripheral vascular 
insufficiency. Changes in cerebral blood flow mirrored these 
findings. 
Concurrently, all laboratory measurements were markedly 
improved. The fall in whole blood viscosity was most rapid in 
the period between presentation and when the PCV reached 
0.5 L·L-1 , being almost in the normal range, and the further 
small decrement to achieve normality occurred with the PCV 
stabilised at 0.4 L·L-1 • These changes are due to the reduction 
in red cell mass as other factors known to effect rheology were 
within the normal range at the start of the study. 
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Similarly, the results of the exercise tests show that 
reduction in the PCV, and hence oxygen carrying capacity per unit 
volume, was not associated with any deterioration in exercise 
tolerance nor demonstrable change in cardiac output during steady 
state exercise. This observation suggests that tissue oxygen 
delivery was improved, despite the reduced oxygen carrying 
capacity, and implies more effective microvascular perfusion 
resulting from the reduced viscosity. Further evidence 
supporting improved tissue perfusion is the progressive increase 
in the ventilatory threshold on incremental exercise97 •98 • This 
fact is also consistent with enhanced oxygen delivery to 
metabolising tissue, with reduction in glycolysis-induced 
hydrogen ion production and more effective removal of metabolic 
breakdown products as a consequence of improved rheology: this 
benefit was clearly evident at 0.5 L·L-1 and was more marked at 
0.4 L·L-1 • An alternative explanation for this phenomenon could 
be improved physical fitness as a result of training. Such a 
postulate can be discounted as the subjects were essentially 
sedentary and maintained similar degrees of activity throughout 
the study. Moreover, maximum exercise capacity was unchanged in 
the group as a whole. There was some individual variability in 
maximum exercise capacity which amounted to approximately one 
workload on the protocol used. This is almost certainly due t o 
the 'stepped' increment in workload of 100 kp·m·min-1 • A 'ramp' 
protocol or smaller 'step' in workload would have allowed for 
greater precision in measurement. 
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Cardiac output and arterial-mixed venous oxygen content 
difference during steady state exercise did not change while 
oxygen consumption was similar at each level of PCV. This 
implies that increased oxygen carriage to the tissues in 
erythrocytosis did not result in appropriate tissue oxygen 
uptake, supplying further evidence that high PCV results in 
impaired tissue perfusion. 
Cerebral blood flow was shown to increase as PCV and whole 
blood viscosity fell. There was a strong relationship between 
arterial oxygen content and cerebral blood flow and there was no 
correlation between cerebral oxygen transport and viscosity. 
This suggests that oxygen delivery to the brain is maintained as 
a result of autoregulation, in keeping with the findings of 
Friedland62 and Marshall 64 • Impaired oxygen transport to the 
brain cannot thus be blamed for the marked neuropsychiatric 
symptoms that are frequently found in erythrocytosis58 •61 • 
Impaired microcirculation, regional ischaemia, accumulation of 
metabolites and sludging due to increased viscosity and reduced 
flow are likely to be responsible for these symptoms. The 
continued improvement in well-being as PCV falls below 0.50 L·L-1 
with increasing cerebral blood flow but no increase in oxygen 
delivery reinforces these postulated mechanisms. 
All the data, whether it be clinical, haematological, 
rheological, or physiological, shows that reduction in PCV below 
the initial presenting value is beneficial. The results at PCV 
0.5 L·L-1 are in keeping with a number of previous studies 
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involving venesection in erythrocytosis due to various causes. 
Of greater significance is the continued improvement when the PCV 
is reduced further into the low normal range. In this group of 
patients with no significant cardiac or respiratory disease there 
is evidence that cerebral blood flow and tissue perfusion are 
better at PCV 0.4 L·L-1 • The results of the exercise tests show 
that the potential disadvantage of decreased oxygen carriage is 
offset by better tissue perfusion. Coupled with the 
theoretical75 and epidemiological56 •57 data cited previously it 
appears that the optimal PCV in patients without cardiac or 
respiratory disease lies close to 0.4 L·L-1 and that this should 
be the target if venesection is undertaken. Iron deficiency may 
result in symptoms or impaired exercise performance following 
venesection, al though the data is inconsistent34 , 35 , 83- 86 • 
The problem of erythrocytosis secondary to severe pulmonary 
disease or cyanotic congenital heart disease, although a separate 
issue, is a cause for considerable clinical concern given the 
extensive evidence for the marked hyperviscosity that occurs when 
the PCV exceeds O. 51 to O. 55 L · L-133 •52 •56 •75 •99 • A marked increase in 
peripheral vascular, coronary and cerebrovascular morbidity 
prevails under these circumstances. 
The recommendations of Perloff et al~~ basea on their 
experience with patients with cyanotic congenital heart disease 
were that venesection was indicated only when patients had 
symptomatic hyperviscosity with PCV greater than 0.65 L·L-1 • 
Their aim of venesection was to withdraw the minimum blood volume 
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required to produce symptomatic relief. They also felt that iron 
deficiency may play an important role in hyperviscosity and 
suggested that hyperviscosity symptoms with PCV less than 
0.65 L·L-1 was due to iron deficiency. They described very few 
vascular or thrombotic complications in their patients. 
These recommendations conflict with the findings in the 
current study in which considerable symptomatic and physiological 
derangements were present with PCV very much lower than the level 
of 0.65 L·L-1 regarded as the threshold for venesection by 
Perloff. There is considerable evidence that these 
recommendations are not appropriate for patients with hypoxic 
lung disease or polycythaemia vera in which considerable benefit 
has been found following venesection from levels 0.60 L·L-1 and 
lower2,45,46,48,79,100. 
Pulmonary function tests have been evaluated previously 
during serial venesection in erythrocytosis, and as shown in this 
study lung volumes and mechanics remain unchanged after 
venesection, even when erythrocy_tosis is secondary to hypoxic 
lung disease2•4•45 •48•79 •100 . Diffusing capacity for carbon monoxide 
has also been studied101-105 . In this study, diffusing capacity 
was shown to be markedly raised compared to the predicted values 
at the high PCV of presentatj :n, with subsequent fall to close to 
predicted values following venesection(figure 4.2). There is 
not, however, a linear relationship between change in PCV or 
haemoglobin and fall in diffusing capacity. The fall seemed 
particularly marked when PCV fell from presentation to 
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0.50 L·L-1 , with a much smaller fall when PCV was further reduced 
to 0.40 L·L-1 (figures 4.3 and 4.4). 
Diffusing capacity measures the transfer of carbon monoxide 
across the alveolar-capillary membrane and subsequent uptake by 
red cells in the pulmonary capillaries1~. This can be 
represented as the sum of resistances: 
1/TLCO = 1/Dm + 1/8·Ve 
where Dm represents a membrane component, e the reaction 
rate of CO with haemoglobin and Ve the effects of haemoglobin 
concentration and pulmonary capillary blood volume. Dm and e are 
unchanged and as haemoglobin concentration does not correlate 
with changes in diffusing capacity the presumption is that the 
pulmonary capillary volume is increased in erythrocytosis and 
falls as PCV returns to within the normal range. This is 
supported by the data of several workers104 •107 • In patients with 
PV, Burgess103 showed that Ve was reduced and postulated that this 
was due to in situ thromboses in the pulmonary microcirculation. 
The initial observations of Burgess103 and Herbert102 that 
diffusing capacity correlated well with haemoglobin concentration 
appear wrong in the light of more recent work, including this 
study. 
Diffusing cap2city is frequently used in the assessment of 
severity of lung disease and is overestimated in erythrocytosis. 
An equation to correct diffusing capacity in anaemia has been 
widely used108 • This equation corrects the diffusing capacity to 
that which should prevail if haemoglobin concentration were 
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146 g·L-1 • In erythrocytosis, however, use of this equation 
results in a falsely high diffusing capacity104 and care needs to 
be exercised when interpreting diffusing capacity values in 
erythrocytotic patients. 
A further separate issue concerns the optimal PCV for 
athletic performance, since there exists among athletes a belief 
that there is an advantage to be gained by increasing haematocrit 
above normal, a practice known as "blood-doping" 109 • Spriet et 
alllO demonstrated an increase in maximal oxygen uptake of almost 
7% when PCV was boosted from O. 46 L · L-1 to O. 51 L · L-1 by the re-
infusion of three units of freeze-stored blood. This finding 
supports previous studies1n,n2 , although conflicting results have 
been reportedll3,n4 • The latter authors have been criticised on 
methodological grounds1~, and there is now consensus that 
increasing the PCV above normal confers benefit in terms of 
performance of endurance exercise. We do not consider these 
findings in athletes to be in conflict with the present study 
undertaken on patients who were sedentary, middle-aged and 
suffering from pathological erythrocytosis. Firstly, athletes 
have an increased capillary bed in the working muscles as a 
component of physical fitnessll 5 and secondly, the effects of re-
infusion on cerebral blood flow and on longer-term morbidity have 
not been studied. The criteria by which PCV is judged to be 




Summary and conclusions 
Nine previously untreated patients with erythrocytosis with 
packed cell volume (PCV) of greater than 0.55 L·L-1 were studied 
at presentation, a second time when the PCV was stabilised at 
0.5 L·L-1 , and again when this value was 0.4 L·L-1 • Studies 
included clinical assessment and the measurement of whole blood 
viscosity, pulmonary function, incremental and steady state 
exercise testing and cerebral blood flow. Reduction in red cell 
mass by controlled venesection was associated with symptomatic 
improvement in all patients. Reduction in PCV from the 
presenting level of 0.61 ± 0.05 L·L-1 to 0.40 ± 0.02 L·L-1 
resulted in a decrease in whole blood viscosity from 10.7 + 3.3 
to 6.2 + 0.8 cP, increased cerebral blood flow from 39.8 + 5.3 to 
52.8 + 8.3 mL·lOOg tissue-1 , and increased ventilatory turnpoint 
from 56.6 + 8.5 % of maximum achieved workload to 72.6 + 11.5 %, 
with no fall in exercise capacity. These changes, which were 
significant at PCV 0.5 L·L-1 , were more ,t'arked at PCV 0.4 L·L-1 • 
These findings support the hypothesis that in patients with 
erythrocytosis the increased oxygen carrying capacity consequent 
upon an expanded red cell mass is without benefit to the patient. 
On the contrary, it would appear that the dominant influence of 
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this phenomenon on symptoms and exercise capacity is an adverse 
one related to impaired tissue perfusion, almost certainly due to 
hyperviscosity. Thus, in individuals with normal or near normal 
cardiovascular and respiratory function, marked benefit to 
metabolising tissues will result from reduction in viscosity 
consequent upon venesection. Oxygen delivery is thus likely to 
be improved, notwithstanding the lower oxygen-carrying capacity 
of blood following venesection. It is notable that reduction in 
the PCV well below the upper normal limit of 0.47 L·L-1 results 
in further clinical and laboratory improvement and the present 
study would support 0.4 L·L-1 rather than 0.5 L·L-1 as a 
reasonable target in any program of venesection for individuals 
who are without cardiovascular or respiratory impairment. Iron 
deficiency may supervene and cause symptoms in its own right. 
This eventuality requires independent evaluation. 
It follows that a reasonable approach in patients with 
arterial hypoxaemia would be the use of a judicious venesection 
program, with careful clinical and physiological, including 
exercise, monitoring to reduce PCV to a level resulting in 
improved cerebral function but without loss of exercise capacity. 
On the basis of this prospective study in which each 
individual acted as his o~ her own control, it is possible to 
conclude that in absolute erythrocytosis reduction in the red 
cell mass by graded venesection to a packed cell volume of 
approximately 0.4 L·L-1 will result in marked symptomatic 
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improvement and this is accompanied by achievement of optimal 
cerebral blood flow and muscle perfusion. 
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Appendix 1: Predicted values in exercise testing 
Maximum heart rate96 : HR = 210 - 0.65 x age(yrs) 
Maximum ventilation117 : = 35 x FEV1 (L) 
If FEV1 < 1.2 L
96 = 20 + (20 x FEV1 ) (L) 
Systolic BP118 : BP5 = 120 + 0.8 x workload(kp·m·min-1 ) 
Diastolic BP should not change more than± 10 mmHg 
Workload92 : V02 (max) = 60 - 0.55 x age(yrs) [ml·kg-1 ·min-1 ] Men 
= 4 8 - 0. 37 x age (yrs) [ml· kg-1 ·min-1 ] Women 
V02 (max) = Above figure x lean body mass [ml·min-1 ] 
Workload = [V02 (max) - 3.5 x mass(kg) ]/2 [kp·m·min-1 ] 
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Appendix 2: Exercise test calculations 
Typical measurements made are: 
Inspired minute ventilation (ATPS) by dry gas meter: 









By convention, lung volumes and ventilation are reported as 
volume (BTPS) - i.e. at 37°C, ambient pressure, fully saturated 
with water vapour. Gas exchange variables (CO2 production and 0 2 
consumption) are reported as volume (STPD) - i.e. at 0°C, 
760 mmHg, dry. Measurements are made at ATPS - atmospheric 
pressure and temperature, fully saturated with water vapour. 
Conversion factors to convert ATPS volumes to BTPS and STPD need 
to be applied. These can be read from tables or calculated from 
the following90 : 
SVP = 9.993 - 0.3952 x TA+ 0.03775 x T/ 
BTPS = (P8 - SVP)/(P8 - 47) X (310/(273 + TA)) 
STPD = (P8 - SVP)/760 x (273/(273 + TA)) 
Ventilatio n measured by dry gas meter or pneumotachograph is 
usually inspired ventilation as this minimises condensation in 
the recording apparatus. The expired ventilation (VE) is usually 
slightly different to V1 because of the respiratory exchange 
ratio (R). The conversion can be made by using the nitrogen 
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content of air, which is assumed to be constant (Haldane's 
correction) 92 • 
FiN2 X V1 == FeN2 X VE 
FiN2 == 1 - Fi02 == 1 - 0.2093 == .7904 
During exercise the most common variables calculated are the 
oxygen consumption (V02 ) and carbon dioxide production (VC02 ). 
Minute ventilation (BTPS) == VE or V1 x BTPS factor 
ml· min-1 ( STPD) 
V02 (STPD) == [V1 (STPD) x 0.2093 - VE (STPD) x Fe02 ] x 1000 
ml· min-1 ( STPD) 
End-tidal PC02 can be calculated from the end-tidal FC02 as 
follows: 
PnC02 == FnC02 x (Pa - 47) mm Hg 
[Use (Pa - 6.3) if working in kPa] 
Cardiac output calculation 
Cardiac output is measured using the Fick principle: 
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The mixed venous-arterial CO2 content difference ( Cv-aC02 ) can 
be calculated using the equation for the CO2 dissociation curve: 
The mixed venous PC02 (PvC02 ) is obtained by the 
equilibration rebreathing method94 •95 • This needs to be corrected 
for the "downstream" effect119 
The calculation for ( Cv-aC02 ) then simplifies to: 
This value has to be corrected for changes in haemoglobin 
concentration120 : 
Corrected (Cv-aC02 ) = (Cv-aC02 ) - (15-[Hb]) x 0.015 X (PvC02 -
pa CO2) 
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